Back to mobile site
Get it on Google Play

FDA offers Acurx path to NDA with single Phase 3 trial for CDI drug

August 3, 2026 8:00 AM EDT Send to a Friend
Acurx Pharmaceuticals (NASDAQ: ACXP) said the FDA has provided guidance indicating it is open to reviewing a New Drug Application ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login